Hula Therapeutics
Hula Therapeutics is a Philadelphia-based, clinical-stage precision immunotherapy company spun out of Dr. John Maris' lab at Children's Hospital of Philadelphia. Its lead program HLTX-001 is a peptide-centric CAR-T therapy in a Phase 1b trial for pediatric neuroblastoma.
- Company typePrivate
- Founded2022
- HeadquartersPhiladelphia, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Hula Therapeutics does
Hula Therapeutics is a clinical-stage precision immunotherapy company developing engineered cell therapies for solid tumors. It was founded in 2022 based on research from Dr. John Maris' laboratory at Children's Hospital of Philadelphia (CHOP) and is headquartered in the Philadelphia region, with the legal entity Hula Therapeutics, Inc. governed under California law. The platform combines immunopeptidomics with novel protein engineering to identify and target intracellular tumor-specific antigens presented on human leukocyte antigen (HLA) molecules — a class of targets that conventional CAR-T approaches cannot reach because they are limited to cell surface antigens. The technology is described as compatible with a variety of immunotherapy modalities and capable of delivering therapeutics across a broad distribution of HLA allotypes, suggesting potential applicability to a wide patient population.
The company's lead product, HLTX-001, is a precision-engineered CAR-T therapy targeting the PHOX2B peptide presented on HLA for neuroblastoma, currently being evaluated in a Phase 1b clinical trial. The pipeline is at an early stage with no disclosed additional programs. Business model is pre-commercial: Hula generates no product revenue today and will, if and when it reaches approval, generate revenue through drug development and commercialization of its pipeline therapies for solid tumor indications, with CAR-T therapies for rare pediatric cancers historically commanding premium pricing. Go-to-market is enterprise field sales targeted at major medical centers and children's hospitals, including a deep co-development partnership with CHOP. Disclosed funding includes a $1.5 million ACGT-Barbara Netter Fund Collaboration Challenge Grant (with matching taking total program investment to $6 million) and a $250,000 financing led by Hatch Biofund Management. Operating geographies are presently domestic (USA) only.
Hula Therapeutics firmographics
Firmographics- Name
- Hula Therapeutics
- Legal name
- Hula Therapeutics, Inc.
- Website
- https://hulatx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Hula Therapeutics is a Philadelphia-based, clinical-stage precision immunotherapy company spun out of Dr. John Maris' lab at Children's Hospital of Philadelphia. Its lead program HLTX-001 is a peptide-centric CAR-T therapy in a Phase 1b trial for pediatric neuroblastoma.
- Ownership category
- akta.pro rank
Hula Therapeutics industry classification
Industry- Product category
- Cell Therapy / Pediatric Oncology Therapeutics
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro industry
- CAR-T & TCR-T TherapiesHigh-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Keywords
Where Hula Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Hula Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: As a clinical-stage precision immunotherapy company, Hula Therapeutics is focused on developing and advancing its lead CAR-T therapy (HLTX-001) through clinical trials. Revenue will be generated upon regulatory approval and commercialization of its pipeline therapies for solid tumor indications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Hula Therapeutics product offering
Product offeringCore offering
Hula Therapeutics is a clinical-stage precision immunotherapy company developing HLTX-001, a peptide-centric CAR-T cell therapy for neuroblastoma currently in a Phase 1b clinical trial. The company combines immunopeptidomics with novel protein engineering to unlock tumor-specific, intracellular targets in solid cancers, with broad HLA allotype compatibility. Its core deliverable is a pipeline of engineered cell therapies for solid tumor indications built on CHOP-originated research.
Product overview
Hula Therapeutics is a clinical-stage precision immunotherapy company developing treatments for solid cancers. The company combines cutting-edge immunopeptidomics with novel protein engineering to identify tumor-specific intracellular targets. Its lead product HLTX-001 is a CAR-T therapy for neuroblastoma in Phase 1b clinical trials, representing the company's primary therapeutic focus.
Differentiator
Problem solved
Functional benefit
Products and services
- HLTX-001 Precision-engineered peptide-centric CAR-T cell therapy for neuroblastoma, targeting the PHOX2B peptide presented on HLA on the cell surface; currently in Phase 1b clinical trial evaluation for pediatric oncology patients with solid tumors.
Quantifiable outcome
- Phase 1b clinical trial enrollment for HLTX-001 in neuroblastoma
Companies that use Hula Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Hula Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Hula Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Children's Hospital of Philadelphia (CHOP)coreHula Therapeutics was built on pioneering research from Dr. John Maris' laboratory at CHOP. The company collaborates with CHOP researchers on the development of HLTX-001, a peptide-centric CAR T-cell therapy for neuroblastoma. This is a deep strategic partnership based on foundational academic research that underpins the company's core technology platform.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Hula Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Hula Therapeutics social profiles
Digital presenceHula Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hula Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Hula Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hula Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hula Therapeutics
What does Hula Therapeutics do?
Hula Therapeutics is a clinical-stage precision immunotherapy company developing HLTX-001, a peptide-centric CAR-T cell therapy for neuroblastoma currently in a Phase 1b clinical trial. The company combines immunopeptidomics with novel protein engineering to unlock tumor-specific, intracellular targets in solid cancers, with broad HLA allotype compatibility. Its core deliverable is a pipeline of engineered cell therapies for solid tumor indications built on CHOP-originated research.
Is Hula Therapeutics a public or private company?
Hula Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hula Therapeutics founded?
Hula Therapeutics was founded in 2022. It employs 1 to 10 people.
Where is Hula Therapeutics based?
Hula Therapeutics is headquartered in Philadelphia, United States, in the North America region.
How does Hula Therapeutics make money?
One revenue line is on record: drug Development and Commercialization.
Does Hula Therapeutics have an API?
No public API is recorded for Hula Therapeutics.
What industry is Hula Therapeutics in?
Hula Therapeutics's product category is Cell Therapy / Pediatric Oncology Therapeutics. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its SIC code is 2836.